Coronavirus Update: WHO director-general calls for moratorium on booster shots
- ByMarketWatch-
Coronavirus Update: WHO director-general calls for moratorium on booster shots
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
Coronavirus Update: WHO director-general calls for moratorium on booster shots
The highly transmissible delta variant of the coronavirus that causes COVID-19 is now in 135 countries, the World Health Organization said Wednesday, as its head called for a...
Stocks reversed earlier gains brought on by strong retail sales data and mixed earnings reports, as worse-than-expected inflation findings weighed on Wall Street.
AstraZeneca, J&J Working On 'Modifications' To Eliminate Potentially Deadly Side EffectsYesterday, the FDA confirmed that the Johnson & Johnson jab may be linked to rare side...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 302.80 | 302.94 | 297.69 | -0.20 | -0.07% | 1.51M | London | |||
| 171.06 | 173.82 | 169.50 | +0.48 | +0.28% | 5.32M | London | |||
| 104.41 | 105.88 | 100.47 | -1.64 | -1.55% | 1.72M | London | |||
| 45.93 | 46.33 | 45.62 | -1.38 | -2.91% | 31.20M | London | |||
| 2,062.00 | 2,065.50 | 1,970.86 | +60.00 | +3.00% | 71.09K | London | |||
| 962.80 | 976.00 | 940.40 | +21.80 | +2.32% | 596.64K | London | |||
| 406.20 | 411.80 | 401.00 | -3.00 | -0.73% | 151.98K | London | |||
| 990.00 | 1,012.00 | 976.00 | -21.00 | -2.08% | 494.81K | London | |||
| 107.73 | 108.53 | 103.85 | +3.19 | +3.05% | 9.69M | London | |||
| 8,360.70 | 8,374.00 | 8,242.00 | +90.0 | +1.09% | 228.71K | London | |||
| 0.59 | 0.00 | 0.00 | +0.070 | +13.46% | 38.73M | London | |||
| 88.00 | 88.00 | 88.00 | 0.00 | 0.00% | 0.00 | London | |||
| 0.15 | 0.00 | 0.00 | -0.0000 | 0.00% | 72.09M | London | |||
| 3,772.50 | 3,784.30 | 3,762.70 | -22.5 | -0.59% | 14.93K | London | |||
| 233.98 | 234.32 | 233.15 | +0.63 | +0.27% | 294.64K | London |
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.